Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced BRAF-mutant Cancers”

35 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 35 results

Testing effectiveness (Phase 2)Study completedNCT03843775
What this trial is testing

Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Who this might be right for
Advanced BRAF Mutant Cancers
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Study completedNCT04059224
What this trial is testing

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

Who this might be right for
Stage IV MelanomaStage III Melanoma
Universitair Ziekenhuis Brussel 45
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Large-scale testing (Phase 3)Ended earlyNCT02967692
What this trial is testing

The Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 568
Early research (Phase 1)Active Not RecruitingNCT05538130
What this trial is testing

Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Who this might be right for
MelanomaGliomaThyroid Cancer+10 more
Pfizer 148
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Early research (Phase 1)UnknownNCT03781219
What this trial is testing

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Who this might be right for
Solid Tumor
Shanghai Kechow Pharma, Inc. 45
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Early research (Phase 1)Study completedNCT01897116
What this trial is testing

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Who this might be right for
Melanoma
Abramson Cancer Center at Penn Medicine 8
Testing effectiveness (Phase 2)Looking for participantsNCT07789210
What this trial is testing

A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases

Who this might be right for
Colorectal CancerBRAF V600E Mutation PositiveEncorafenib+1 more
Zhejiang University 25
Testing effectiveness (Phase 2)Study completedNCT01512251
What this trial is testing

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Who this might be right for
BRAF Mutant Metastatic Melanoma
University of California, San Francisco 8
Early research (Phase 1)Study completedNCT03864042
What this trial is testing

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Melanoma
Pfizer 56
Large-scale testing (Phase 3)WithdrawnNCT02427893
What this trial is testing

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Who this might be right for
Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)WithdrawnNCT03972046
What this trial is testing

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Who this might be right for
Melanoma (Skin)Melanoma Stage IIIb-IVM1aMetastasis Skin+2 more
TriHealth Inc.
Testing effectiveness (Phase 2)Study completedNCT01320085
What this trial is testing

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Who this might be right for
BRAF or NRAS Mutant Metastatic Melanoma
Pfizer 183
Testing effectiveness (Phase 2)UnknownNCT05370807
What this trial is testing

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

Who this might be right for
Melanoma Stage IIIMelanoma Stage IV
Universitair Ziekenhuis Brussel 48
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Early research (Phase 1)Ended earlyNCT05501912
What this trial is testing

ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorBRAF V600 Mutation
ABM Therapeutics Shanghai Company Limited 20
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Early research (Phase 1)Ended earlyNCT02974725
What this trial is testing

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Who this might be right for
Non-Small Cell Lung CancerMelanoma
Novartis Pharmaceuticals 241
Next Page